Compare TATT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TATT | GYRE |
|---|---|---|
| Founded | 1985 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.4M | 606.4M |
| IPO Year | 2002 | 2004 |
| Metric | TATT | GYRE |
|---|---|---|
| Price | $40.98 | $6.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $57.17 | $17.00 |
| AVG Volume (30 Days) | ★ 225.2K | 107.1K |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $275,000.00 |
| Revenue This Year | $16.29 | $19.88 |
| Revenue Next Year | $16.09 | N/A |
| P/E Ratio | $38.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.36 | $5.44 |
| 52 Week High | $64.50 | $9.42 |
| Indicator | TATT | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 43.03 |
| Support Level | $40.85 | $5.59 |
| Resistance Level | $41.91 | $8.28 |
| Average True Range (ATR) | 2.24 | 0.34 |
| MACD | -0.75 | -0.09 |
| Stochastic Oscillator | 22.69 | 14.55 |
TAT Technologies Ltd provides solutions and services to the commercial and military aerospace and ground defense industries, focused mainly on three product areas and services: Thermal Management, Power and Actuation, and Maintenance, Repair and Overhaul (MRO). Its product portfolio includes heat exchangers, cooling systems, and mechanical aircraft accessories and systems such as pumps, valves, and turbine power units. Its operating segments are MRO services for aviation components, which derive key revenue, Original equipment manufacturing (OEM) of heat transfer solutions and aviation accessories, MRO services for heat transfer components and OEM of heat transfer solutions, and Overhaul and coating of jet engine components. Geographically, it derives key revenue from the United States.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.